01—Abstract
Summary
Summary of the 8-K filed April 17, 2020. Cited figures are marked; the original filing is the authoritative source.
Moderna, Inc. (MRNA) announced a significant development on April 16, 2020, through an 8-K filing detailing a material definitive agreement.
The company entered into a contract with the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services. This BARDA Contract provides up to $483 milliona in funding to accelerate the development of Moderna's mRNA vaccine candidate (mRNA-1273) for the novel coronavirus (SARS-CoV-2). The funding from BARDA will support the advancement of mRNA-1273 through clinical studies and manufacturing for those studies, with the ultimate goal of achieving potential licensure.
The contract includes a base period of performance aimed at preparing a biologics license application, with options for extensions that could extend the total contract period to over five years. While this represents substantial non-dilutive funding and validation for Moderna's COVID-19 vaccine efforts, investors should note customary government contract terms, including the government's right to terminate the contract for convenience.
02—Key points
Key Highlights
- Moderna entered into a material definitive agreement with BARDA, a U.S. government entity.
- The BARDA Contract provides up to $483 million in funding for Moderna's mRNA-1273 vaccine candidate against SARS-CoV-2.
- Funding will support clinical studies and manufacturing for the COVID-19 vaccine.
- The contract aims to advance mRNA-1273 towards potential licensure.
- The base period of performance focuses on preparing a biologics license application.
- The total contract period, including options, can extend up to approximately five years and six months.
- The agreement includes customary government contract terms, such as the right to terminate for convenience.
03—Questions
Frequently Asked Questions
What is the primary purpose of the BARDA Contract?
The primary purpose of the BARDA Contract is to provide significant funding of up to $483 million to accelerate the development of Moderna's mRNA vaccine candidate (mRNA-1273) for COVID-19. This funding will support crucial activities such as clinical studies and manufacturing required for regulatory approval and potential licensure.
How will the $483 million be disbursed?
The $483 million is an award that could result in payments to Moderna. The contract includes a base period of performance, with potential option exercises that could extend the total contract period. The BARDA funding is specifically designated for advancing the vaccine candidate through clinical trials and associated manufacturing.
Are there any risks associated with this BARDA Contract for Moderna?
While the BARDA contract provides substantial funding, it contains customary terms for government contracts. This includes a provision allowing the government to terminate the contract at any time for its convenience. Investors should be aware of this as a potential risk, though the funding itself represents a strong endorsement and critical resource for the vaccine development.
What does 'potential licensure' mean in the context of this agreement?
Potential licensure refers to the goal of developing the mRNA-1273 vaccine candidate to a point where it can be approved by regulatory authorities (like the FDA) for widespread use. The BARDA funding is intended to cover the costs of the necessary clinical trials and manufacturing processes that are prerequisites for submitting a biologics license application (BLA) and obtaining such approval.
04—Continue